PHASE IV RANDOMISED DOUBLE-MASKED CLINICAL TRIAL: ASSESSING MORNING VERSUS EVENING DOSING OF A FIXED DOSE COMBINATION OF TRAVOPROST 0.004% / TIMOLOL MALEATE 0.5% IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION: